Calixar signs exclusive licensing agreement with Regeneron on undisclosed therapeutic target

April 29, 2019

Calixar has given Regeneron exclusive rights to its technology and expertise to conduct research and discovery of antibodies against an undisclosed target in various therapeutic fields.

Read the article

Conformational antibody development

Vaccine development

Ligand high-throughput screening

Structure-based drug discovery

Immunoassays

Deorphanization projects

Identification of relevant targets

Expression of full-length membrane proteins

Functional isolation and stabilization of targets

Conformational antibody development

Vaccine development

High-throughput ligand screening

Structure-based drug discovery

Immunoassays

Deorphanization projects

Identification of relevant targets

Expression of full-length membrane proteins

Functional isolation and stabilization of targets

Secure and boost
your discovery programs.

Starting from native material or recombinant systems, we succeed with all types of membrane proteins: GPCRs, Ion Channels, Transporters, Receptors and Viral Proteins.